Endocyte Inc

Endocyte — Technical Presentation (December 2011)

17 slides from Endocyte's technical presentation, Dec 13, 2011

  1. Slide 1: Supplemental PRECEDENT Trial Analysis

    Endocyte Inc. Supplemental PRECEDENT Trial Analysis December 13, 2011 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements During the course of this presentation, we will make forward-looking statements regarding future events and our future performance. The words “believe”, “anticipate”, “expect”, “estimate”, “intend”, “plan”, “may”, “will” and other similar expressions generally identify for

  3. Slide 3: PRECEDENT Trial Supplemental Analysis

    PRECEDENT Trial Supplemental Analysis Purpose Results Validate EC20 to select FR positive patients Validated (inter-reader agreement 85%) Test robustness of PFS primary endpoint (investigator assessed) PFS robust (no evidence of bias) Confirmed PFS results in FR(++) group Update OS analysis (102 eve

  4. Slide 4: Platinum-Resistant Ovarian Cancer Is an Attractive Patient Population for Drug Approvals

    Platinum resistant ovarian cancer patients (failed first or second platinum therapy < 6 months) EC145 + PLD PLD only FR Positive Platinum-Resistant Ovarian Cancer Is an Attractive Patient Population for Drug Approvals • Platinum-resistant ovarian cancer overall survival 12.7 months • Current drugs d

  5. Slide 5: Validates EC20

    EC20 Validates Reader Agreement FR(+) > 1 positive lesion 87% FR(++) all lesions positive 85% Independent reader study validates EC20 to select FR positive patients for phase 3 study Targeted >70% agreement

  6. Slide 6: Investigator PFS Assessment Passed

    Investigator PFS Assessment Passed Standard Battery of Tests for Robustness Test for Imbalances Pass / Fail Results Patient populations Pass Adjusted for imbalances in patient prognostic factors (e.g. performance status) HR 0.597* Study discontinuance Pass Treat discontinuance as event HR 0.610* Cli

  7. Slide 7: As Expected Treatment Arm Median Decreased More Than Control Arm

    As Expected Treatment Arm Median Decreased More Than Control Arm Note: of patients with > follow up CT scan – EC145/PLD and PLD

  8. Slide 8: Investigator and IRC PFS Results

    Investigator and IRC PFS Results FR(++) results are statistically significant and clinically meaningful in both analyses

  9. Slide 9: PFS Conclusions

    PFS Conclusions • Primary endpoint (investigator assessed PFS) is robust and unbiased • IRC confirmed statistically significant and clinically meaningful results in FR(++) group • Greater confidence that phase 2 results can be repeated in phase 3 (blinded) confirmatory study

  10. Slide 10: Historical PLD Phase Trials in Platinum Resistant Ovarian Cancer

    Historical PLD Phase 3 Trials in Platinum Resistant Ovarian Cancer Study Drug N OS Gordon et al. (2004) PLD 8.3 Topotecan 9.5 Mutch et al. (2007) PLD 13.5 Gemcitabine 12.7 Ferrandina et al. (2008) PLD 12.7 Gemcitabine 11.5 Vergote et al. (2009) PLD or Topotecan 13.5 Canfosfamide 8.5 Monk et al. (201

  11. Slide 11: Overall Survival Underpowered and Indeterminate

    Overall Survival Underpowered and Indeterminate Overall Survival ITT n=149 FR(++) n=38 EC145/PLD PLD EC145/PLD PLD Median (months) 14.1 16.9 14.0 16.4 Hazard Ratio (95% CI) 1.099 (0.722, 1.673) 1.420 (0.631, 3.194) 6-month Survival Rate 81% 70% 73% 60% 12-month Survival Rate 62% 63% 64% 53% • ITT OS

  12. Slide 12: 2:1 Randomization Introduced Greater Variability in Control Arm OS Curve

    2:1 Randomization Introduced Greater Variability in Control Arm OS Curve Months ITT Patient Population EC145 + PLD (n=100) PLD Alone (n=49) PRECEDENT PLD control survival is more than 4 months longer than historic EC145/PLD Median PLD Median

  13. Slide 13: Imbalance in PFI and Post-Trial Platinum Therapy May Have Confounded OS Results

    Imbalance in PFI and Post-Trial Platinum Therapy May Have Confounded OS Results % of Patients ITT FR(++) EC145/PLD PLD EC145/PLD PLD > 3 months platinum free interval* 56% 76% 57% 73% Received post-study chemotherapy 70% 71% 65% 80% Platinum 18% 33% 17% 27% Topotecan 34% 31% 44% 33% Gemcitabine 27%

  14. Slide 14: Exploratory Analysis OS

    OS Exploratory Analysis Overall Survival Hazard Ratio Population (events by arm) N (1) Unadjusted Analysis Adjusted Analysis (2) ITT ( events: 70/32) 1.099 0.928 FR(++) (events: 18/10) 1.420 0.495 1. EC20 scan assessment available for 94 of 149 patients. 2. Results from Cox proportional hazards mode

  15. Slide 15: Overall Survival Conclusions

    Overall Survival Conclusions • Underpowered, particularly in the control arm (49 patients) • Control arm curve median is significantly longer than in historical PLD trials • Imbalance in platinum free interval and post platinum therapy may have impacted results • Results inconclusive

  16. Slide 16: Implications for Phase 3 Study

    Implications for Phase 3 Study • Validation of EC20 allows us to focus on FR(++) population • Higher confidence that phase 2 results repeated in phase 3 study • Primary endpoint of phase 3 on blinded investigator reads • Include platinum free interval in stratification • 1:1 Randomization FR(++) Pop

  17. Slide 17: Questions & Answers

    Questions & Answers

Endocyte — Technical Presentation (December 2011) on 6ix